Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study

BACKGROUND: Up to 6-months oxaliplatin-containing regimen is now widely accepted as a standard adjuvant chemotherapy for stage III colorectal cancer (CRC). However, oral fluoropyrimidine monotherapy is used for some part of patients, especially in Asian countries including Japan, and its optimal dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Naohiro, Kunieda, Katsuyuki, Maeda, Atsuyuki, Hamada, Chikuma, Yamanaka, Takeharu, Sato, Toshihiko, Yoshida, Kazuhiro, Boku, Narikazu, Nezu, Riichiro, Yamaguchi, Shigeki, Mishima, Hideyuki, Sadahiro, Sotaro, Muro, Kei, Ishiguro, Megumi, Sakamoto, Junichi, Saji, Shigetoyo, Maehara, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461756/
https://www.ncbi.nlm.nih.gov/pubmed/30833647
http://dx.doi.org/10.1038/s41416-019-0410-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461756/
https://www.ncbi.nlm.nih.gov/pubmed/30833647
http://dx.doi.org/10.1038/s41416-019-0410-0

Ejemplares similares